NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the third quarter ended September 30, 2023.

Adam Levy, NEXGEL’s Chief Executive Officer, commented, “We are pleased to deliver yet another record revenue quarter of $1.2 million, an increase of 115% year-over-year, driven by growth year-over-year in both contract manufacturing and branded consumer products. Importantly, gross margins during the third quarter improved sequentially to 28.2% as compared to 15.0% in the prior second quarter. Our net loss also continued to trend lower quarter-over-quarter, in line with our goal to become profitable in 2024.”

Mr. Levy continued, “We have a lot to be excited about as we near the close of 2023 and head into the new year. Given our growth into retail with Enigma Health as well as partnerships with AbbVie and others, we have strategically invested in inventory and equipment to increase capacity and automation to meet the significant increase in demand we expect for our proprietary hydrogels. We expect our revenue growth year-over-year, margin expansion and net loss decrease trend to continue in the short term as we optimize our operations and growth opportunities come to fruition.”

Operational Highlights in 2023

  • NEXGEL’s subsidiary, CG Converting and Packaging, executed a new supply agreement with AbbVie (NYSE: ABBV), a global biopharmaceutical company to be a supplier of gel pads with AbbVie’s Rapid Acoustic Pulse device being investigated for improvement in the appearance of cellulite.
  • Announced a new strategic relationship with Enigma Health, a new joint venture company, for retail distribution and marketing services in North America.

Third Quarter 2023 Financial Highlights

For the third quarter of 2023, revenue totaled $1.2 million, an increase of $653 thousand or 115%, as compared to $568 thousand for the same period the year prior. The quarterly increase in overall revenues was primarily due to sales growth in contract manufacturing and branded products year-over-year, including revenue contribution from the joint venture formed with C.G. Laboratories.

Gross profit for the third quarter of 2023 was $344 thousand, compared to a gross profit of $148 thousand for the same prior year period. Gross profit margin for the third quarter of 2023 was 28.2% as compared to 26.1% for the same period the year prior. Gross profit margin increased sequentially to 28.2% during the third quarter of 2023 as compared to 15.0% during the second quarter of 2022.

Total operating expenses, including R&D and SG&A expenses, decreased to $956 thousand for the three months ended September 30, 2023, compared to $1,185 thousand for the prior year period. The year-over-year decrease was attributable to a decrease in total SG&A and the completion of development efforts of two proof of concept studies for drug delivery candidates utilizing our hydrogel technology.

Net loss for the quarter ended September 30, 2023, improved to $550 thousand or $0.10 per basic and diluted share, compared to net loss of $1.2 million or $0.22 per basic and diluted share for the same period in 2022. Net loss also improved sequentially to $550 thousand during the third quarter of 2023 as compared to $642 thousand during the second quarter of 2023.

As of September 30, 2023, NEXGEL had approximately $3.3 million of cash. The delta between our improved net loss during the quarter and net cash decrease period over period relates to an increase in account receivables, and property, plant and equipment investments.

As of November 13, 2023, NEXGEL had 5,717,629 shares of common stock outstanding.

NEXGEL Third Quarter 2023 Financial Results Conference Call

Management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss its operational and financial results for the third quarter 2023.

Date: November 13, 2023Time: 4:30 P.M. ETLive Call: +1-877-407-9208 (U.S. Toll Free) or +1-201-493-6784 (International)Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1640412&tp_key=d1c55ca731

For interested individuals unable to join the conference call, a replay will be available through November 27, 2023, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13742264. An archived version of the webcast will also be available on NEXGEL’s Investor Relations site: https://ir.nexgel.com/.

About NEXGEL, INC.NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2022, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

Investor Contacts:Valter Pinto, Managing DirectorKCSA Strategic Communications212.896.1254valter@kcsa.com

NEXGEL, INCCONDENSED CONSOLIDATED BALANCE SHEETS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 (Unaudited)(in thousands, except share and per share data)

    September 30,2023     December 31,2022  
ASSETS:                
Current Assets:                
Cash   $ 3,266     $ 1,101  
Marketable securities     -       5,508  
Accounts receivable, net     1,158       222  
Inventory     1,090       502  
Prepaid expenses and other current assets     367       172  
Total current assets     5,881       7,505  
Goodwill     311       311  
Intangibles, net     12       20  
Property and equipment, net     1,737       721  
Operating lease - right of use asset     1,911       1,737  
Other assets     95       63  
Total assets   $ 9,947     $ 10,357  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current Liabilities:                
Accounts payable   $ 1,073     $ 265  
Accrued expenses and other current liabilities     152       130  
Deferred revenue     34       -  
Current portion of note payable     5       15  
Warrant liability     146       242  
Operating lease liability, current portion     233       207  
Total current liabilities     1,643       859  
Operating lease liability, net of current portion     1,774       1,593  
Notes payable, net of current portion     274       268  
Total liabilities     3,691       2,720  
                 
Commitments and Contingencies (Note 15)                
                 
STOCKHOLDERS’ EQUITY                
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding     -       -  
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 5,717,629 and 5,577,916 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively     6       6  
Additional paid-in capital     19,309       19,189  
Accumulated deficit     (13,617 )     (11,558 )
Total NexGel stockholders’ equity     5,698       7,637  
Non-controlling interest in joint venture     558       -  
Total stockholders’ equity     6,256       7,637  
Total liabilities and stockholders’ equity   $ 9,947     $ 10,357  

NEXGEL, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited)(in thousands, except share and per share data)

    Three Months Ended     Nine Months Ended  
    September 30,     September 30,  
    2023     2022     2023     2022  
Revenues, net   $ 1,221     $ 568     $ 3,007     $ 1,524  
                                 
Cost of revenues     877       420       2,546       1,304  
                                 
Gross profit     344       148       461       220  
                                 
Operating expenses                                
Research and development     6       193       90       328  
Selling, general and administrative     950       992       2,629       2,459  
Total operating expenses     956       1,185       2,719       2,787  
                                 
Loss from operations     (612 )     (1,037 )     (2,258 )     (2,567 )
                                 
Other income (expense)                                
Interest expense     (3 )     (242 )     (13 )     (1,334 )
Interest income     1       -       3       -  
Loss on debt extinguishment     -       -       -       (150 )
Warrant modification expense     -       (57 )     -       (57 )
Other income     -       -       3       2  
Gain on investments     44       5       168       5  
Changes in fair value of warrant liability     18       104       96       3  
Total other income (expense), net     60       (190 )     257       (1,531 )
Loss before income taxes     (552 )     (1,227 )     (2,001 )     (4,098 )
Income tax expense     -       -       -       -  
Net loss   $ (552 )   $ (1,227 )   $ (2,001 )   $ (4,098 )
Less: (Income) loss attributable to non-controlling interest in joint venture     2       -       (58 )     -  
Net loss attributable to NexGel stockholders     (550 )     (1,227 )     (2,059 )     (4,098 )
Net loss per common share - basic   $ (0.10 )   $ (0.22 )   $ (0.36 )   $ (0.74 )
Net loss per common share - diluted   $ (0.10 )   $ (0.22 )   $ (0.36 )   $ (0.74 )
Weighted average shares used in computing net loss per common share - basic     5,714,316       5,572,234       5,654,981       5,572,234  
Weighted average shares used in computing net loss per common share – diluted     5,714,316       5,572,234       5,654,981       5,572,234  

NEXGEL, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 (Unaudited)(in thousands)

    Nine Months Ended September 30,  
    2023     2022  
Operating Activities                
Net loss   $ (2,059 )   $ (4,098 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Income attributable to non-controlling interest in joint venture     58       -  
Depreciation and amortization     103       84  
Changes in ROU asset and operating lease liability     33       29  
Share-based compensation and restricted stock vesting     120       231  
Gain on investment in marketable securities     168       (5 )
Changes in fair value of warrant liability and warrant modification     (96 )     (3 )
Amortization of deferred financing costs     -       1,325  
Warrant modification expense     -       57  
Loss on extinguishment of debt     -       150  
                 
Changes in operating assets and liabilities:                
Accounts receivable     (936 )     (56 )
Inventory     (588 )     (108 )
Prepaid expenses and other assets     (227 )     (162 )
Accounts payable     808       104  
Accrued expenses and other current liabilities     (67 )     109  
Deferred revenue     34       -  
Net Cash Used in Operating Activities     (2,649 )     (2,343 )
                 
Investing Activities                
Proceeds from sales of marketable securities     5,340       1,000  
Investment in marketable securities     -       (6,980 )
Capital expenditures     (611 )     (88 )
Net Cash Provided by (Used in) Investing Activities     4,729       (6,068 )
                 
Financing Activities                
Proceeds from margin line of credit     89       -  
Principle payments of notes payable     (4 )     (3,512 )
Net Cash Provided by (Used in) Financing Activities     85       (3,512 )
Net Increase (Decrease) in Cash     2,165       (11,923 )
Cash – Beginning of period     1,101       13,350  
Cash – End of period   $ 3,266     $ 1,427  
Supplemental Disclosure of Cash Flows Information                
Cash paid during the year for:                
Interest   $ 7     $ -  
Taxes   $ -     $ -  
                 
Supplemental Non-cash Investing and Financing activities                
Property and equipment contributed as capital investment to JV   $ 500     $ -  
ROU asset and operating lease liabilities recognized upon consolidation of JV   $ 334     $ -  
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jan 2024 to Feb 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2023 to Feb 2024 Click Here for more AbbVie Charts.